TGM3, a candidate tumor suppressor gene, contributes to human head and neck cancer

Molecular Cancer

Volumn 12, Issue 1, 2013, Pages

  Wu, Xiangbing ^a,b   Cao, Wei ^a,b   Wang, Xu ^a,b   Zhang, Jianjun ^a,b   Lv, Zhongjing ^a,b   Qin, Xing ^a,b   Wu, Yadi ^b   Chen, Wantao ^a,b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Shanghai Key Laboratory of Stomatology   (China)

Author keywords

Head and neck cancer; Methylation; Prognostic predictor; Transglutaminase 3; Tumor suppressor

Indexed keywords

ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; GFP PROTEIN; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 3; UNCLASSIFIED DRUG;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GENE THERAPY; CANCER INHIBITION; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CANCER TISSUE; CARCINOGENESIS; CARCINOGENICITY; CELL PROLIFERATION; CELL SURVIVAL; COLONY FORMATION; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DNA SEQUENCE; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENE FUNCTION; GENE SILENCING; GENETIC ASSOCIATION; GENETIC TRANSCRIPTION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO GENE TRANSFER; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; OVERALL SURVIVAL; PROMOTER REGION; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE GENE; REAL TIME POLYMERASE CHAIN REACTION; RNA TRANSLATION; TISSUE DIFFERENTIATION; TREATMENT OUTCOME; TUMOR DIFFERENTIATION; TUMOR SUPPRESSOR GENE; TUMOR VOLUME; WESTERN BLOTTING;

ADULT; AGED; ANIMALS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; DNA METHYLATION; DOWN-REGULATION; ENZYME REPRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENES, TUMOR SUPPRESSOR; HEAD AND NECK NEOPLASMS; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MIDDLE AGED; NEOPLASM TRANSPLANTATION; PROMOTER REGIONS, GENETIC; PROPORTIONAL HAZARDS MODELS; RNA, MESSENGER; TRANSGLUTAMINASES; TUMOR BURDEN;

EID: 84888355842     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-12-151     Document Type: Article

References (46)

1. Mignogna MD, Fedele S, Lo Russo L. The World Cancer Report and the burden of oral cancer. Eur J Cancer Prev 2004, 13:139-142.
2. Forastiere A, Koch W, Trotti A, Sidransky D. Head and neck cancer. N Engl J Med 2001, 345:1890-1900. 10.1056/NEJMra001375, 11756581.
3. Le Tourneau C, Faivre S, Siu LL. Molecular targeted therapy of head and neck cancer: review and clinical development challenges. Eur J Cancer 2007, 43:2457-2466. 10.1016/j.ejca.2007.08.016, 17904355.
4. Wheeler SE, Suzuki S, Thomas SM, Sen M, Leeman-Neill RJ, Chiosea SI, Kuan CT, Bigner DD, Gooding WE, Lai SY, Grandis JR. Epidermal growth factor receptor variant III mediates head and neck cancer cell invasion via STAT3 activation. Oncogene 2010, 29:5135-5145. 10.1038/onc.2009.279, 2940981, 20622897.
5. Chung CH, Parker JS, Karaca G, Wu J, Funkhouser WK, Moore D, Butterfoss D, Xiang D, Zanation A, Yin X, et al. Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell 2004, 5:489-500. 10.1016/S1535-6108(04)00112-6, 15144956.
6. Bentzen SM, Atasoy BM, Daley FM, Dische S, Richman PI, Saunders MI, Trott KR, Wilson GD. Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial. J Clin Oncol 2005, 23:5560-5567. 10.1200/JCO.2005.06.411, 16110017.
7. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674. 10.1016/j.cell.2011.02.013, 21376230.
8. Mohr S, Leikauf GD, Keith G, Rihn BH. Microarrays as cancer keys: an array of possibilities. J Clin Oncol 2002, 20:3165-3175. 10.1200/JCO.2002.12.073, 12118031.
9. Belbin TJ, Singh B, Smith RV, Socci ND, Wreesmann VB, Sanchez-Carbayo M, Masterson J, Patel S, Cordon-Cardo C, Prystowsky MB, Childs G. Molecular profiling of tumor progression in head and neck cancer. Arch Otolaryngol Head Neck Surg 2005, 131:10-18. 10.1001/archotol.131.1.10, 15655179.
10. Chin D, Boyle GM, Williams RM, Ferguson K, Pandeya N, Pedley J, Campbell CM, Theile DR, Parsons PG, Coman WB. Novel markers for poor prognosis in head and neck cancer. Int J Cancer 2005, 113:789-797. 10.1002/ijc.20608, 15499618.
11. Kuriakose MA, Chen WT, He ZM, Sikora AG, Zhang P, Zhang ZY, Qiu WL, Hsu DF, McMunn-Coffran C, Brown SM, et al. Selection and validation of differentially expressed genes in head and neck cancer. Cell Mol Life Sci 2004, 61:1372-1383. 10.1007/s00018-004-4069-0, 15170515.
12. Hitomi K, Horio Y, Ikura K, Yamanishi K, Maki M. Analysis of epidermal-type transglutaminase (TGase 3) expression in mouse tissues and cell lines. Int J Biochem Cell Biol 2001, 33:491-498. 10.1016/S1357-2725(01)00033-4, 11331204.
13. Hitomi K. Transglutaminases in skin epidermis. Eur J Dermatol 2005, 15:313-319.
14. Hitomi K, Presland RB, Nakayama T, Fleckman P, Dale BA, Maki M. Analysis of epidermal-type transglutaminase (transglutaminase 3) in human stratified epithelia and cultured keratinocytes using monoclonal antibodies. J Dermatol Sci 2003, 32:95-103. 10.1016/S0923-1811(03)00091-4, 12850301.
15. Kalinin AE, Kajava AV, Steinert PM. Epithelial barrier function: assembly and structural features of the cornified cell envelope. Bioessays 2002, 24:789-800. 10.1002/bies.10144, 12210515.
16. Eckert RL, Sturniolo MT, Broome AM, Ruse M, Rorke EA. Transglutaminase function in epidermis. J Invest Dermatol 2005, 124:481-492. 10.1111/j.0022-202X.2005.23627.x, 15737187.
17. He G, Zhao Z, Fu W, Sun X, Xu Z, Sun K. Study on the loss of heterozygosity and expression of transglutaminase 3 gene in laryngeal carcinoma. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2002, 19:120-123.
18. Uemura N, Nakanishi Y, Kato H, Saito S, Nagino M, Hirohashi S, Kondo T. Transglutaminase 3 as a prognostic biomarker in esophageal cancer revealed by proteomics. Int J Cancer 2009, 124:2106-2115. 10.1002/ijc.24194, 19142970.
19. Negishi A, Masuda M, Ono M, Honda K, Shitashige M, Satow R, Sakuma T, Kuwabara H, Nakanishi Y, Kanai Y, et al. Quantitative proteomics using formalin-fixed paraffin-embedded tissues of oral squamous cell carcinoma. Cancer Sci 2009, 100:1605-1611. 10.1111/j.1349-7006.2009.01227.x, 19522851.
20. Mendez E, Fan W, Choi P, Agoff SN, Whipple M, Farwell DG, Futran ND, Weymuller EA, Zhao LP, Chen C. Tumor-specific genetic expression profile of metastatic oral squamous cell carcinoma. Head Neck 2007, 29:803-814. 10.1002/hed.20598, 17573689.
21. Lu SL, Herrington H, Reh D, Weber S, Bornstein S, Wang D, Li AG, Tang CF, Siddiqui Y, Nord J, et al. Loss of transforming growth factor-beta type II receptor promotes metastatic head-and-neck squamous cell carcinoma. Genes Dev 2006, 20:1331-1342. 10.1101/gad.1413306, 1472907, 16702406.
22. Hasina R, Hulett K, Bicciato S, Di Bello C, Petruzzelli GJ, Lingen MW. Plasminogen activator inhibitor-2: a molecular biomarker for head and neck cancer progression. Cancer Res 2003, 63:555-559.
23. Erjala K, Sundvall M, Junttila TT, Zhang N, Savisalo M, Mali P, Kulmala J, Pulkkinen J, Grenman R, Elenius K. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells. Clin Cancer Res 2006, 12:4103-4111. 10.1158/1078-0432.CCR-05-2404, 16818711.
24. Van Tubergen E, Vander Broek R, Lee J, Wolf G, Carey T, Bradford C, Prince M, Kirkwood KL, D'Silva NJ. Tristetraprolin regulates interleukin-6, which is correlated with tumor progression in patients with head and neck squamous cell carcinoma. Cancer 2011, 117:2677-2689. 10.1002/cncr.25859, 3574798, 21656745.
25. Han J, Kioi M, Chu WS, Kasperbauer JL, Strome SE, Puri RK. Identification of potential therapeutic targets in human head & neck squamous cell carcinoma. Head Neck Oncol 2009, 1:27. 10.1186/1758-3284-1-27, 2719634, 19602232.
26. Grandis JR. Prognostic biomarkers in head and neck cancer. Clin Cancer Res 2006, 12:5005-5006. 10.1158/1078-0432.CCR-06-1356, 16951212.
27. Schaaij-Visser TB, Graveland AP, Gauci S, Braakhuis BJ, Buijze M, Heck AJ, Kuik DJ, Bloemena E, Leemans CR, Slijper M, Brakenhoff RH. Differential proteomics identifies protein biomarkers that predict local relapse of head and neck squamous cell carcinomas. Clin Cancer Res 2009, 15:7666-7675. 10.1158/1078-0432.CCR-09-2134, 19996216.
28. Molling JW, Langius JA, Langendijk JA, Leemans CR, Bontkes HJ, van der Vliet HJ, von Blomberg BM, Scheper RJ, van den Eertwegh AJ. Low levels of circulating invariant natural killer T cells predict poor clinical outcome in patients with head and neck squamous cell carcinoma. J Clin Oncol 2007, 25:862-868. 10.1200/JCO.2006.08.5787, 17327607.
29. Petrik D, Lavori PW, Cao H, Zhu Y, Wong P, Christofferson E, Kaplan MJ, Pinto HA, Sutphin P, Koong AC, et al. Plasma osteopontin is an independent prognostic marker for head and neck cancers. J Clin Oncol 2006, 24:5291-5297. 10.1200/JCO.2006.06.8627, 17114663.
30. Marsit CJ, Posner MR, McClean MD, Kelsey KT. Hypermethylation of E-cadherin is an independent predictor of improved survival in head and neck squamous cell carcinoma. Cancer 2008, 113:1566-1571. 10.1002/cncr.23770, 3645304, 18711702.
31. Liu J, Zhou Y, Wan J, Liu Z. Expression of TGM3 protein and its significance in laryngeal carcinoma. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2012, 26:101-103.
32. Lallemant B, Evrard A, Combescure C, Chapuis H, Chambon G, Raynal C, Reynaud C, Sabra O, Joubert D, Hollande F, et al. Clinical relevance of nine transcriptional molecular markers for the diagnosis of head and neck squamous cell carcinoma in tissue and saliva rinse. BMC Cancer 2009, 9:370. 10.1186/1471-2407-9-370, 2767357, 19835631.
33. Ye H, Yu T, Temam S, Ziober BL, Wang J, Schwartz JL, Mao L, Wong DT, Zhou X. Transcriptomic dissection of tongue squamous cell carcinoma. BMC Genomics 2008, 9:69. 10.1186/1471-2164-9-69, 2262071, 18254958.
34. Chen BS, Wang MR, Xu X, Cai Y, Xu ZX, Han YL, Wu M. Transglutaminase-3, an esophageal cancer-related gene. Int J Cancer 2000, 88:862-865. 10.1002/1097-0215(20001215)88:6<862::AID-IJC4>3.0.CO;2-L, 11093806.
35. Gonzalez HE, Gujrati M, Frederick M, Henderson Y, Arumugam J, Spring PW, Mitsudo K, Kim HW, Clayman GL. Identification of 9 genes differentially expressed in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2003, 129:754-759.
36. Luo A, Kong J, Hu G, Liew CC, Xiong M, Wang X, Ji J, Wang T, Zhi H, Wu M, Liu Z. Discovery of Ca2 + -relevant and differentiation-associated genes downregulated in esophageal squamous cell carcinoma using cDNA microarray. Oncogene 2004, 23:1291-1299. 10.1038/sj.onc.1207218, 14647409.
37. Ohkura S, Kondoh N, Hada A, Arai M, Yamazaki Y, Sindoh M, Takahashi M, Matsumoto I, Yamamoto M. Differential expression of the keratin-4, -13, -14, -17 and transglutaminase 3 genes during the development of oral squamous cell carcinoma from leukoplakia. Oral Oncol 2005, 41:607-613. 10.1016/j.oraloncology.2005.01.011, 15975524.
38. Liu W, Yu ZC, Cao WF, Ding F, Liu ZH. Functional studies of a novel oncogene TGM3 in human esophageal squamous cell carcinoma. World J Gastroenterol 2006, 12:3929-3932.
39. Kondoh N, Ishikawa T, Ohkura S, Arai M, Hada A, Yamazaki Y, Kitagawa Y, Shindoh M, Takahashi M, Ando T, et al. Gene expression signatures that classify the mode of invasion of primary oral squamous cell carcinomas. Mol Carcinog 2008, 47:744-756. 10.1002/mc.20431, 18449855.
40. Choi P, Jordan CD, Mendez E, Houck J, Yueh B, Farwell DG, Futran N, Chen C. Examination of oral cancer biomarkers by tissue microarray analysis. Arch Otolaryngol Head Neck Surg 2008, 134:539-546. 10.1001/archotol.134.5.539, 2578846, 18490578.
41. Lorand L, Graham RM. Transglutaminases: crosslinking enzymes with pleiotropic functions. Nat Rev Mol Cell Biol 2003, 4:140-156. 10.1038/nrm1014, 12563291.
42. Griffin M, Casadio R, Bergamini CM. Transglutaminases: nature's biological glues. Biochem J 2002, 368:377-396. 10.1042/BJ20021234, 1223021, 12366374.
43. Candi E, Schmidt R, Melino G. The cornified envelope: a model of cell death in the skin. Nat Rev Mol Cell Biol 2005, 6:328-340. 10.1038/nrm1619, 15803139.
44. Cao W, Feng Z, Cui Z, Zhang C, Sun Z, Mao L, Chen W. Up-regulation of enhancer of zeste homolog 2 is associated positively with cyclin D1 overexpression and poor clinical outcome in head and neck squamous cell carcinoma. Cancer 2012, 118:2858-2871. 10.1002/cncr.26575, 21989926.
45. Feng Z, Guo W, Zhang C, Xu Q, Zhang P, Sun J, Zhu H, Wang Z, Li J, Wang L, et al. CCND1 as a predictive biomarker of neoadjuvant chemotherapy in patients with locally advanced head and neck squamous cell carcinoma. PLoS One 2011, 6:e26399. 10.1371/journal.pone.0026399, 3204964, 22065993.
46. Cao W, Zhang ZY, Xu Q, Sun Q, Yan M, Zhang J, Zhang P, Han ZG, Chen WT. Epigenetic silencing of MAL, a putative tumor suppressor gene, can contribute to human epithelium cell carcinoma. Mol Cancer 2010, 9:296. 10.1186/1476-4598-9-296, 3002926, 21092172.